The Expanding Roles of B Cells in Systemic Sclerosis: From Autoantibody Production to Antibody-Independent Functions and Therapeutic Targeting
Sclerosis · 01.08.2026 · 4 (3) · 22
DOI: 10.3390/sclerosis4030022 ↗Kurz gefasst
Fachartikel in der Zeitschrift Sclerosis, online erschienen am 01.08.2026. Verfasst von Takashi Matsushita. Die Arbeit nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Systemic sclerosis (SSc) is a rare, clinically heterogeneous connective tissue disease defined by the triad of autoimmunity, microvasculopathy, and fibrosis of the skin and internal organs. Among the immune effectors implicated in SSc, B cells have moved from being regarded mainly as the source of disease-defining autoantibodies to being recognized as multifunctional drivers of disease through antibody-independent mechanisms. This review summarizes current understanding of B-cell biology in SSc across three domains. First, we consider the classical role of B cells as antibody-producing cells, including the diagnostic and prognostic value of SSc-specific autoantibodies, the evidence for polyclonal B-cell activation and altered B-cell homeostasis, and the contested question of autoantibody pathogenicity. Second, we examine antibody-independent functions, focusing on cytokine production by effector and regulatory B-cell subsets, the B-cell-activating factor (BAFF) axis, antigen presentation, and T-cell co-stimulation, together with the imbalance between pro-inflammatory effector B cells and interleukin (IL)-10-producing regulatory B cells that characterizes active disease. Third, we review B cells as therapeutic targets, from the rituximab experience—including the randomized DESIRES trial and its open-label extension—through anti-BAFF strategies to the emerging use of CD19-directed chimeric antigen receptor (CAR) T-cell and CAR-natural killer (NK) cell therapies that achieve deep, durable B-cell depletion. We conclude by highlighting unresolved questions, including patient selection, the balance between depleting pathogenic and protective B-cell subsets, biomarker development, and the long-term safety of deep B-cell depletion. A B-cell-centered view of SSc pathogenesis provides a coherent framework that links autoimmunity to fibrosis and is increasingly translatable into the clinic.
Zitieren
APA
Matsushita, T. (2026). The Expanding Roles of B Cells in Systemic Sclerosis: From Autoantibody Production to Antibody-Independent Functions and Therapeutic Targeting. Sclerosis, 4(3), 22. https://doi.org/10.3390/sclerosis4030022
Vancouver
Matsushita T. The Expanding Roles of B Cells in Systemic Sclerosis: From Autoantibody Production to Antibody-Independent Functions and Therapeutic Targeting. Sclerosis. 2026;4(3):22. doi:10.3390/sclerosis4030022
BibTeX
@article{Matsushita2026,
author = {Matsushita, Takashi},
title = {The Expanding Roles of B Cells in Systemic Sclerosis: From Autoantibody Production to Antibody-Independent Functions and Therapeutic Targeting},
journal = {Sclerosis},
year = {2026},
volume = {4},
number = {3},
pages = {22},
doi = {10.3390/sclerosis4030022}
}
EUVIMED